Patents by Inventor Katerine Van Rietschoten
Katerine Van Rietschoten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970555Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TfR1. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, and multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder through TfR1 mediated delivery of a therapeutic agent.Type: GrantFiled: November 12, 2021Date of Patent: April 30, 2024Assignee: BicycleTx LimitedInventors: Ellen Gowans, Gemma Elizabeth Mudd, Michael Rigby, Punit Seth, Michael Skynner, Steven Stanway, Liudvikas Urbonas, Katerine Van Rietschoten
-
Publication number: 20240108737Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly the spike protein S1 of SARS-CoV-2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by infection of SARS-CoV-2 or for providing prophylaxis to a subject at risk of infection of SARS-CoV-2.Type: ApplicationFiled: January 10, 2022Publication date: April 4, 2024Inventors: Nicholas KEEN, Gemma MUDD, Katerine VAN RIETSCHOTEN, Katie GAYNOR, Liuhong CHEN, Maximilian HARMAN, Michael SKYNNER, Paul BESWICK, Mehdi AMOURA, Simone GIORGI, Giulia LATTANZI, Iain LINGARD
-
Publication number: 20240091368Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders of ACE2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by ACE2, such as infection of COVID-19 or for providing prophylaxis to a subject at risk of infection of COVID-19.Type: ApplicationFiled: January 10, 2022Publication date: March 21, 2024Inventors: Nicholas KEEN, Katerine VAN RIETSCHOTEN, Liuhong CHEN, Maximilian HARMAN, Paul BESWICK, Paul BESWICK
-
Publication number: 20240083944Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly the spike protein S1 of SARS-CoV-2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by infection of SARS-CoV-2 or for providing prophylaxis to a subject at risk of infection of SARS-CoV-2.Type: ApplicationFiled: January 10, 2022Publication date: March 14, 2024Inventors: Nicholas KEEN, Gemma MUDD, Katerine VAN RIETSCHOTEN, Katie GAYNOR, Liuhong CHEN, Maximilian HARMAN, Michael SKYNNER, Paul BESWICK, Mehdi AMOURA, Simone GIORGI, Giulia LATTANZI, Iain LINGARD
-
Patent number: 11912792Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: GrantFiled: August 17, 2022Date of Patent: February 27, 2024Assignee: BicycleTx LimitedInventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
-
Publication number: 20240000957Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: ApplicationFiled: May 8, 2023Publication date: January 4, 2024Inventors: Liuhong CHEN, Philip HUXLEY, Silvia PAVAN, Katerine VAN RIETSCHOTEN
-
Patent number: 11833211Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: GrantFiled: September 23, 2022Date of Patent: December 5, 2023Assignee: BicycleTx LimitedInventors: Liuhong Chen, Philip Huxley, Silvia Pavan, Katerine Van Rietschoten
-
Publication number: 20230287047Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: ApplicationFiled: August 17, 2022Publication date: September 14, 2023Inventors: Paul BESWICK, Liuhong CHEN, Gemma MUDD, Peter PARK, Katerine VAN RIETSCHOTEN, Michael RIGBY
-
Patent number: 11696956Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: GrantFiled: December 19, 2018Date of Patent: July 11, 2023Assignee: BicycleTx LimitedInventors: Liuhong Chen, Philip Huxley, Silvia Pavan, Katerine Van Rietschoten
-
Publication number: 20230183291Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of ACE2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by ACE2, such as infection of COVID-19 or for providing prophylaxis to a subject at risk of infection of COVID-19.Type: ApplicationFiled: May 14, 2021Publication date: June 15, 2023Inventors: Nicholas KEEN, Katerine VAN RIETSCHOTEN, Liuhong CHEN, Maximilian HARMAN, Michael SKYNNER, Paul BESWICK, Yuliya DEMYDCHUK
-
Publication number: 20230144799Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: ApplicationFiled: September 23, 2022Publication date: May 11, 2023Inventors: Liuhong CHEN, Philip HUXLEY, Silvia Pavan, Katerine Van Rietschoten
-
Patent number: 11623012Abstract: The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and dmg conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: GrantFiled: December 19, 2018Date of Patent: April 11, 2023Assignee: BicycleRD LimitedInventors: Liuhong Chen, Silvia Pavan, Catherine Stace, Daniel Teufel, Katerine Van Rietschoten
-
Publication number: 20230106511Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of penicillin-binding proteins (PBPs) more particularly PBP3. The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in suppressing or treating a disease or disorder mediated by bacterial infection or for providing prophylaxis to a subject at risk of infection.Type: ApplicationFiled: February 26, 2021Publication date: April 6, 2023Inventors: Matthew BALMFORTH, Paul BESWICK, Liuhong CHEN, Mike DAWSON, Rachel DODS, Catherine ROWLAND, Michael SKYNNER, Katerine VAN RIETSCHOTEN
-
Patent number: 11484602Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: GrantFiled: December 14, 2018Date of Patent: November 1, 2022Assignee: BicycleTx LimitedInventors: Liuhong Chen, Philip Huxley, Silvia Pavan, Katerine Van Rietschoten
-
Publication number: 20220306689Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.Type: ApplicationFiled: December 23, 2019Publication date: September 29, 2022Inventors: Liuhong CHEN, James COOKE, Kevin MCDONNELL, Gemma MUDD, Katerine VAN RIETSCHOTEN, Punit UPADHYAYA
-
Patent number: 11453702Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: GrantFiled: September 30, 2021Date of Patent: September 27, 2022Assignee: BICYCLETX LIMITEDInventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
-
Publication number: 20220289792Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: ApplicationFiled: December 19, 2018Publication date: September 15, 2022Inventors: Liuhong CHEN, Philip HUXLEY, Silvia PAVAN, Katerine VAN RIETSCHOTEN
-
Publication number: 20220281918Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of penicillin-binding proteins (PBPs). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in suppressing or treating a disease or disorder mediated by bacterial infection or for providing prophylaxis to a subject at risk of infection.Type: ApplicationFiled: August 28, 2020Publication date: September 8, 2022Inventors: Katerine VAN RIETSCHOTEN, Paul BESWICK, Mike DAWSON, Matthew BALMFORTH, Michael SKYNNER, Liuhong CHEN
-
Patent number: 11396530Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: October 28, 2020Date of Patent: July 26, 2022Assignee: BICYCLETX LIMITEDInventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
-
Publication number: 20220194988Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TfR1. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, and multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder through TfR1 mediated delivery of a therapeutic agent.Type: ApplicationFiled: November 12, 2021Publication date: June 23, 2022Inventors: Ellen GOWANS, Gemma Elizabeth MUDD, Michael RIGBY, Punit SETH, Michael SKYNNER, Steven STANWAY, Liudvikas URBONAS, Katerine VAN RIETSCHOTEN